| An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study (NCT06736509) | Axsome Therapeutics, Inc. | 2024-11-21 |
| A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation (NCT05557409) | Axsome Therapeutics, Inc. | 2022-09-06 |
| A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation (NCT04947553) | Axsome Therapeutics, Inc. | 2021-06-17 |
| Assessing Clinical Outcomes in Alzheimer's Disease Agitation (NCT04797715) | Axsome Therapeutics, Inc. | 2020-12-31 |
| Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type (NCT04464564) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2020-09-11 |
| Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type (NCT04408755) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2020-07-13 |
| Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type (NCT03393520) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2017-10-13 |
| Addressing Dementia Via Agitation-Centered Evaluation (NCT03226522) | Axsome Therapeutics, Inc. | 2017-07-13 |
| Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type (NCT02446132) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2015-11-13 |
| Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type (NCT02442765) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2015-07-23 |